A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer

In brief

This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab or mFOLFOX in patients with metastatic or advanced solid tumors.

Key facts

Study ID

NCT05346484

Run by

Imugene Limited

People needed

66

Starts

2022-05-17

Expected to finish

2026-01-12

Last updated by the study team

2026-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent from patient or legally authorized representative
• Age ≥ 18 years old on the date of consent
• IT/IV cohorts: Any metastatic or advanced solid tumor with documented radiological progression following at least two prior lines of treatment (which may have included prior immune checkpoint inhibitor (ICI) treatment). Expansion cholangiocarcinoma IT and IV cohorts: one prior line of chemotherapy in metastatic/advanced setting. Patients with targetable tumor mutations must have also received 1 line of approved targeted therapy.
• Expansion cholangiocarcinoma IV cohort: prior treatment with leucovorin calcium, fluorouracil, or oxaliplatin is not permitted.
• ECOG performance status 0 - 2
• At least one measurable lesion
• For IT administration, ideally < 5 total lesions no greater than 10cm and <33% of liver volume replaced by tumor.
• Adequate renal function
• Adequate liver function
• Adequate hematologic function
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

You may not qualify if…

• Prior treatment with a poxvirus based oncolytic virus.
• Continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment.
• Prior radiotherapy within 2 weeks of start of study treatment.
• Active autoimmune disease
• Prior allogenic tissue/organ transplant or other medical conditions requiring ongoing treatment with immunosuppressive drugs or any condition resulting in a systemic immunosuppressed state
• Inadequate pulmonary function per Investigator assessment.
• Uncontrolled brain or other central nervous system (CNS) metastases.
• History of documented congestive heart failure (New York Heart Association [NYHA] class III - IV), unstable angina, poorly controlled hypertension, clinically significant valvular heart disease or high-risk uncontrolled arrhythmias

Where it is running

• University of Arizona Cancer Center — Tucson, Arizona, United States
• Highlands Oncology — Springdale, Arkansas, United States
• City of Hope Medical Center — Duarte, California, United States
• UC San Diego Moores Cancer Center — La Jolla, California, United States
• University of Miami — Miami, Florida, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Corewell Health — Grand Rapids, Michigan, United States
• University of Cincinnati — Cincinnati, Ohio, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States
• NEXT Oncology — Fairfax, Virginia, United States
• Tasman Oncology Research — Southport, Queensland, Australia
• St. Vincent's Hospital — Fitzroy, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.